计算溶液所需的质量、体积或浓度。
LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM; K i =226 nM). LIT-001 improves social interaction in a mouse model of autism
In Vitro
In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Oprm1 –/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background) Dosage: 10, 20 mg/kg Administration: i.p. Result: Alleviated core symptoms in the context of ASD.
IC50& Target:EC50: 55 nM (OT-R), Ki: 226 nM (OT-R)